Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.605
-0.025 (-0.54%)
Sep 15, 2025, 2:42 PM EDT - Market open
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $719.00K in the quarter ending June 30, 2025, with 163.37% growth. This brings the company's revenue in the last twelve months to $2.31M, up 510.85% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$2.31M
Revenue Growth
+510.85%
P/S Ratio
419.58
Revenue / Employee
$42,759
Employees
54
Market Cap
987.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
Dec 31, 2021 | 20.38M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ATAI News
- 6 days ago - Atai Life Sciences N.V. (ATAI) Presents at H.C. - Seeking Alpha
- 17 days ago - atai Life Sciences to Participate in September Investor Conferences - GlobeNewsWire
- 6 weeks ago - Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus - Seeking Alpha
- 7 weeks ago - Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
- 7 weeks ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 7 weeks ago - Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial - Reuters
- 7 weeks ago - Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia - GlobeNewsWire
- 2 months ago - Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD - Seeking Alpha